Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen Inc (BIIB) Q4 2025 Earnings Call Highlights: Strong Growth in Key Products Amidst Revenue Challenges
04:02pm, Friday, 06'th Feb 2026
Revenue: Total revenue for the full year 2025 was $9.9 billion, up 2% versus 2024.Non-GAAP EPS: Fourth quarter non-GAAP diluted EPS was $1.99; full year non-GA
Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
02:14pm, Friday, 06'th Feb 2026
Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View
12:30pm, Friday, 06'th Feb 2026
Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.
Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:30am, Friday, 06'th Feb 2026
The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide
08:59am, Friday, 06'th Feb 2026
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
Biogen Inc. (BIIB) Q4 Earnings and Revenues Top Estimates
08:15am, Friday, 06'th Feb 2026
Biogen Inc. (BIIB) came out with quarterly earnings of $1.99 per share, beating the Zacks Consensus Estimate of $1.61 per share. This compares to earnings of $3.44 per share a year ago.
Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.
07:35am, Friday, 06'th Feb 2026
Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.
Biogen forecasts annual profit above estimates as Leqembi sales pick up
06:10am, Friday, 06'th Feb 2026
Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines and its Alzheimer's treatment Leqembi as older multiple sclerosis drugs battle pressure from ch
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
07:30am, Wednesday, 04'th Feb 2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nature Medicine published results from the Phase 2/3 DEVOTE study evaluating the high-dose regimen o
These Are The Worst 25 Stocks to Own in February
02:57pm, Tuesday, 03'rd Feb 2026
It's been an interesting start to the year, with plenty of geopolitical developments for investors to unpack.
New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings
09:00am, Tuesday, 03'rd Feb 2026
Biogen heads into Q4 earnings with MS drug pressure, while Leqembi and Skyclarys' growth could help offset declines ahead of its Feb. 6 report.
National Pension Service Raises Holdings in Biogen Inc. $BIIB
03:25am, Tuesday, 03'rd Feb 2026
National Pension Service raised its holdings in Biogen Inc. (NASDAQ: BIIB) by 4.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fi
New York State Common Retirement Fund Buys 3,220 Shares of Biogen Inc. $BIIB
05:14am, Monday, 02'nd Feb 2026
New York State Common Retirement Fund boosted its stake in Biogen Inc. (NASDAQ: BIIB) by 2.3% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fir
Great Lakes Advisors LLC Takes $1.33 Million Position in Biogen Inc. $BIIB
04:08am, Monday, 02'nd Feb 2026
Great Lakes Advisors LLC acquired a new stake in shares of Biogen Inc. (NASDAQ: BIIB) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commissi
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of “Hold” by Analysts
02:00am, Monday, 02'nd Feb 2026
Biogen Inc. (NASDAQ: BIIB - Get Free Report) has received an average rating of "Hold" from the twenty-seven brokerages that are presently covering the stock, MarketBeat reports. One research analyst h
